Compare TRDA & ATGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | ATGL |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.8M | 348.8M |
| IPO Year | 2021 | 2023 |
| Metric | TRDA | ATGL |
|---|---|---|
| Price | $10.29 | $20.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 167.3K | 13.6K |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,520,000.00 | $1,206,460.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.36 |
| 52 Week Low | $4.93 | $9.01 |
| 52 Week High | $18.76 | $57.32 |
| Indicator | TRDA | ATGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 44.28 |
| Support Level | $9.89 | $19.81 |
| Resistance Level | $11.55 | $21.19 |
| Average True Range (ATR) | 0.51 | 1.86 |
| MACD | -0.21 | -0.60 |
| Stochastic Oscillator | 25.90 | 13.84 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Alpha Technology Group Ltd operates through its subsidiaries, which are established cloud-based IT solution service providers in Hong Kong. Its Operating Subsidiaries utilize its analytic skills, programming skills, artificial intelligence technologies and technological know-how to provide comprehensive solutions designed to optimize the business performance of customers, meet various industry-specific operational challenges of customers and create new business opportunities for customers. The Operating Subsidiaries provide services for customers from a variety of industries, including consulting, real estate, architectural design, carpark management, electronic payment services, logistics, investments, retail, textiles, wholesale and distribution, etc.